Drew Adams

3.0k total citations
44 papers, 1.1k citations indexed

About

Drew Adams is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Drew Adams has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 9 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Drew Adams's work include Protein Degradation and Inhibitors (10 papers), MicroRNA in disease regulation (5 papers) and Ubiquitin and proteasome pathways (5 papers). Drew Adams is often cited by papers focused on Protein Degradation and Inhibitors (10 papers), MicroRNA in disease regulation (5 papers) and Ubiquitin and proteasome pathways (5 papers). Drew Adams collaborates with scholars based in United States, Japan and Austria. Drew Adams's co-authors include Stuart L. Schreiber, Alykhan F. Shamji, Bridget K. Wagner, Andrew M. Stern, Mingji Dai, David A. Evans, Dharmaraja Allimuthu, Mohamed E. Abazeed, Stefan Kubicek and Melissa M. Kemp and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Investigation.

In The Last Decade

Drew Adams

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Drew Adams United States 18 706 180 174 172 163 44 1.1k
Klaus Pors United Kingdom 20 563 0.8× 250 1.4× 194 1.1× 264 1.5× 171 1.0× 61 1.0k
Benjamin Le Calvé Belgium 20 818 1.2× 345 1.9× 229 1.3× 264 1.5× 159 1.0× 31 1.6k
Hartmut Rehwinkel Germany 17 462 0.7× 163 0.9× 249 1.4× 214 1.2× 54 0.3× 29 1.3k
Andrew S. Tasker United States 20 681 1.0× 482 2.7× 114 0.7× 230 1.3× 62 0.4× 45 1.4k
Zhifei Cao China 23 791 1.1× 165 0.9× 361 2.1× 306 1.8× 186 1.1× 54 1.4k
Urs Regenass Switzerland 23 860 1.2× 194 1.1× 133 0.8× 315 1.8× 58 0.4× 43 1.3k
Tanya Coleman United Kingdom 17 589 0.8× 147 0.8× 88 0.5× 282 1.6× 115 0.7× 28 1.1k
Sébastien Sauvage Belgium 15 1.0k 1.5× 247 1.4× 118 0.7× 171 1.0× 121 0.7× 20 1.5k
Eric Trottier Canada 11 737 1.0× 148 0.8× 312 1.8× 235 1.4× 245 1.5× 13 1.1k

Countries citing papers authored by Drew Adams

Since Specialization
Citations

This map shows the geographic impact of Drew Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Adams more than expected).

Fields of papers citing papers by Drew Adams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Adams. The network helps show where Drew Adams may publish in the future.

Co-authorship network of co-authors of Drew Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Adams. A scholar is included among the top collaborators of Drew Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Adams. Drew Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fedorov, Yuriy, et al.. (2025). Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates. Nature Communications. 16(1). 6548–6548. 2 indexed citations
2.
Yan, David, et al.. (2025). XPO1-Targeting Selective Inhibitors of Transcriptional Activation Suppress Graft-versus-Host Disease. Journal of Medicinal Chemistry. 68(11). 12141–12171. 1 indexed citations
3.
Yan, David, et al.. (2024). Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules. Journal of Medicinal Chemistry. 67(14). 12033–12054. 5 indexed citations
4.
Allan, Kevin, David Yan, Suzanne L. Tomchuck, et al.. (2024). Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation. Nature Chemical Biology. 20(10). 1260–1271. 10 indexed citations
5.
Rana, Priyanka S., James J. Ignatz-Hoover, Byung‐Gyu Kim, et al.. (2024). HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer Research Communications. 4(6). 1517–1532. 5 indexed citations
6.
Adams, Drew, et al.. (2024). C646 degrades Exportin-1 to modulate p300 chromatin occupancy and function. Cell chemical biology. 31(7). 1363–1372.e8. 6 indexed citations
7.
Rana, Priyanka S., James J. Ignatz-Hoover, Amber L. Mosley, et al.. (2024). Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity. Molecular Cancer Therapeutics. 23(12). 1743–1760. 9 indexed citations
8.
Yan, David, et al.. (2024). Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities. ACS Chemical Biology. 19(4). 896–907.
9.
Adams, Drew, et al.. (2024). Therapeutic targeting of exportin-1 beyond nuclear export. Trends in Pharmacological Sciences. 46(1). 20–31. 3 indexed citations
10.
Morgan, Christopher E., Yuriy Fedorov, Surajit Banerjee, et al.. (2023). Discovery of Nonretinoid Inhibitors of CRBP1: Structural and Dynamic Insights for Ligand-Binding Mechanisms. ACS Chemical Biology. 18(10). 2309–2323. 5 indexed citations
11.
Kumar, Mukesh, Robert J. Gaivin, Shenaz Khan, et al.. (2023). Definition of fatty acid transport protein-2 (FATP2) structure facilitates identification of small molecule inhibitors for the treatment of diabetic complications. International Journal of Biological Macromolecules. 244. 125328–125328. 11 indexed citations
12.
Hubler, Zita, et al.. (2022). Enhancers of Human and Rodent Oligodendrocyte Formation Predominantly Induce Cholesterol Precursor Accumulation. ACS Chemical Biology. 17(8). 2188–2200. 12 indexed citations
13.
Caprariello, Andrew V. & Drew Adams. (2022). The landscape of targets and lead molecules for remyelination. Nature Chemical Biology. 18(9). 925–933. 23 indexed citations
14.
Hubler, Zita, David Yan, Ilya Bederman, et al.. (2021). Inhibition of SC4MOL and HSD17B7 shifts cellular sterol composition and promotes oligodendrocyte formation. RSC Chemical Biology. 3(1). 56–68. 9 indexed citations
15.
Hubler, Zita, et al.. (2021). Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation. Cell chemical biology. 28(6). 866–875.e5. 23 indexed citations
16.
Hubler, Zita, et al.. (2021). Screening Reveals Sterol Derivatives with Pro-Differentiation, Pro-Survival, or Potent Cytotoxic Effects on Oligodendrocyte Progenitor Cells. ACS Chemical Biology. 16(7). 1288–1297. 9 indexed citations
17.
Allimuthu, Dharmaraja & Drew Adams. (2017). 2-Chloropropionamide As a Low-Reactivity Electrophile for Irreversible Small-Molecule Probe Identification. ACS Chemical Biology. 12(8). 2124–2131. 35 indexed citations
18.
Chie, Eui Kyu, et al.. (2015). Radiotherapy in the Era of Precision Medicine. Seminars in Radiation Oncology. 25(4). 227–236. 23 indexed citations
19.
Abazeed, Mohamed E., Drew Adams, Kristen E. Hurov, et al.. (2013). Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer. Cancer Research. 73(20). 6289–6298. 90 indexed citations
20.
Bošković, Žarko, Mahmud M. Hussain, Drew Adams, Mingji Dai, & Stuart L. Schreiber. (2013). Synthesis of piperlogs and analysis of their effects on cells. Tetrahedron. 69(36). 7559–7567. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Klaus Pors Breakdown of academic impact, for papers by Benjamin Le Calvé Breakdown of academic impact, for papers by Hartmut Rehwinkel Breakdown of academic impact, for papers by Andrew S. Tasker Breakdown of academic impact, for papers by Zhifei Cao Breakdown of academic impact, for papers by Urs Regenass Breakdown of academic impact, for papers by Tanya Coleman Breakdown of academic impact, for papers by Sébastien Sauvage Breakdown of academic impact, for papers by Eric Trottier
Rankless by CCL
2026